



## **Ventripoint and at the Mazankowski Heart Institute to Collaborate to Conduct a World-First Study of the Changes in Cardiac Function during Pregnancy**

**Toronto, Ontario – The Newswire – March 1, 2022** - Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) will be supporting a world-first study on maternal cardiovascular changes during pregnancy, which will be conducted at the Mazankowski Alberta Heart Institute in Edmonton, Alberta, Canada.

Dr. Lisa Hornberger, Principal Investigator of study stated “We are very grateful to Ventripoint for their support through equipment of this exciting research endeavor. We know that women with heart disease, particularly congenital (from birth) heart disease have an increased risk of poor pregnancy outcomes. This Heart & Stroke Foundation of Canada funded research will explore the contribution of inadequate heart function (use of Ventripoint) and vascular health and their interaction to adverse pregnancy outcomes. Use of the Ventripoint system will facilitate cardiac function investigations even in women with more challenging heart geometry. It is anticipated this innovative work will lead to improved strategies to optimize the cardiovascular health of these mothers leading to healthier pregnancies and infants.”

Dr. Jonathan Windram, Co-investigator stated “We are grateful to Ventripoint for their continued support. The Ventripoint system has been proven to assess ventricular volumes and systolic function in patients with a variety of cardiac conditions and we are excited to have the ability to use this technology within our study.”

Cardiovascular disease complicates 1-4% of pregnancies and is more common in women with hypertensive disorders, which is the leading cause of maternal death (Ramlakhan, K.P., Johnson, M.R. & Roos-Hesselink, J.W, 2020). One of the areas of focus for the study will be looking at the vascular and ventricular function in pregnant women with cardiovascular disease.

A combination of vascular measuring techniques and heart assessments will be used to understand ventricular and vascular interactions in mothers during pregnancy. A study of this nature has never been attempted before and will provide fundamental information on changes in cardiac function during pregnancy.

The VMS+3.0 will be used to perform heart assessments in this study and will allow for quick, accurate and repeat measurements in this groundbreaking study of women’s health. The VMS+3.0 is gaining more traction in being used to assess different heart conditions in specific population groups due to its ease of use and accessibility.

The study is being funded by the Canadian Institutes of Health Research (CIHR), which is Canada's federal funding agency for health research. CIHR funds approximately one billion dollars each year to support the discoveries and innovations that improve health and strengthen the healthcare system.

### **About the Mazankowski Alberta Heart Institute**



The Mazankowski Alberta Heart Institute is one of the leading cardiac centers in Canada. The Principal Investigator of the study, Dr. Lisa Hornberger, was the founder and initial Director of the University of Alberta's Fetal and Neonatal Cardiology Program and the current Section Head of Pediatric Echocardiography.

### **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams  
[gadams@venripoint.com](mailto:gadams@venripoint.com)  
519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

### **Forward Looking Statements**

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify

forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at [www.sedar.com](http://www.sedar.com). Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.